Shubham Pant, MD, on the Future of Treatment of Pancreatic Cancer With Targeted Therapies


Shubham Pant, MD, highlights the importance of tailoring treatment in patients with pancreatic cancer by exploring biomarkers.

In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, Shubham Pant, MD, associate professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discussed the importance of next-generation sequencing (NGS) in gastrointestinal malignancies such as pancreatic cancer and the future role of targeted therapies.


[In terms of] where I see these research efforts [going], I’m going to [use] pancreatic cancer as an example because that’s something that I treat a lot. We can now find these needles in a haystack [with regard to biomarkers]. FGFR mutations and fusions [occur in] about 1% to 2% [of patients with] pancreatic cancer. The response [to targeted therapy is] around 30%. It’s an encouragement and we recommend that all physicians or medical oncologists who are treating pancreatic cancer do next-generation sequencing testing on their patients so we can identify these [markers]. We’re really getting towards this cadre of targeted therapies in patients with pancreatic cancer. We have 1% [of patients] with NRG1 fusions, 1% with NTRK fusions, and 1% to 2% [have microsatellite instability]. This all adds up to quite a lot. That’s one of the big take home messages from this. If the drug is hitting the driver mutation target and we can get good responses even in hard to treat tumors.


Loriot Y, Schuler MH, Iyer G, et al. Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results. J Clin Oncol. 2022;40(suppl 16):3007. doi: 10.1200/JCO.2022.40.16_suppl.3007

Related Videos
An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.
Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.
An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Related Content